It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

eCM - eCells & Materials Journal - Manuscript - Osteogenesis imperfecta - Clinical and molecular diversity - True Open Access

eCM Journal
Created by Scientists, for Scientists

ISSN 1473-2262   NLM: 100973416 (link) The leading Journal of musculoskeletal research.
 

Home

Issues / Manuscripts

 

Supplements

Conferences

 About eCM Journal

 

 Scope

 Submission Instructions

 Editors

 Info on eCM

 Sponsors

 Societies

 Contact

 eCM Paper notification

 

  (Info)

 eCM Site search

 
 
 
   
 


2003   Volume No 5 - pages 41-47

Title: Osteogenesis imperfecta - Clinical and molecular diversity

Authors: P.J. Roughley, F. Rauch and F.H. Glorieux

Address: Genetics Unit, Shriners Hospital for Children, Montreal, Canada

E-mail: proughley at shriners.mcgill.ca

Key Words: Osteogenesis imperfecta, bone, type I colla-gen, gene mutation, bisphosphonate therapy, classification.

Publication date: 30th June 2003

Abstract: Osteogenesis imperfecta is a heritable disorder of bone formation resulting in low bone mass and a propensity to fracture. It exhibits a broad range of clinical severity, ranging from multiple fracturing in utero and perinatal death to normal adult stature and a low fracture incidence. The disorder is currently classified into seven types based on differences in clinical presentation and bone architecture. Mutation in one of the type I collagen genes is commonly associated with osteogenesis imperfecta, but is not a prerequisite for the diagnosis. Indeed, the newer forms of osteogenesis imperfecta (types V, VI and VII) are not associated with type I collagen gene defects. Amongst the type I collagen gene mutations that can occur, missense base substitutions involving glycine codons in the exons encoding the central triple-helix forming domain predominate. Such mutations can occur in all the classical forms of osteogenesis imperfecta (types I-IV), but genotype/phenotype correlations are complex and often unpredictable. Treatment of osteogenesis imperfecta by bisphosphonate therapy can improve bone mass in all types of the disorder, and while not being a cure for the disorder does improve the quality of life of the patient.

Article download: Pages 41-47 (PDF file)

Acrobat Reader:
 

To read this article you will need to install Adobe Acrobat Reader on your computer. Should you experience any difficulty in reading the PDF file we suggest that you save the file to your computer BEFORE opening it from Adobe Acrobat.

Last modified December 18, 2012

Open Access / Author retains copyright

AO Foundation, Davos, Switzerland